Gyrolab® Bioaffy™ CDs are key components of the open Gyrolab platform. Gyrolab CD-based immunoassays are widely used in many applications and a selection of CDs are available that meets the needs for developing immunoassays in a range of assay formats over a broad range of concentrations and for a variety of matrices. A CD-based immunoassay delivers 96 or 112 datapoints in less than an hour.
The proprietary CD technology is engineered with highly reproducible microfluidic structures that ensure high-precision volume definition and tight control over the workflow Precise, and automated control of centrifugal forces and capillary actions steer liquid flow through the microfluidic structures within the CD. Integration in Gyrolab systems enables parallel processing of 96 or 112 microstructures coupled with laser-induced fluorescence detection.
Gyrolab Bioaffy CDs differ primarily in the volume of sample volume processed, which determines the sensitivity of the assay (Figure 2). Many assays can be run using Gyrolab Bioaffy 200 which processes 200 nL. For highest sensitivity, Gyrolab Bioaffy 1000 or Gyrolab Bioaffy 4000 are the CDs of choice.
Gyrolab Bioaffy 4000 CD is the newest member of Gyrolab Bioaffy CD family. Gyrolab Bioaffy 4000 offers extended sensitivity for PK- and biomarker applications compared to Gyrolab Bioaffy 1000. Gyrolab Bioaffy 4000 is based on the proven design of Gyrolab Bioaffy 1000 and uses a deeper volume definition structure to pass 4000 nL of sample over the streptavidin bed. As a result, sufficient analyte is captured from low concentration samples to increase immunoassay sensitivity by 2–6 fold compared with Gyrolab Bioaffy 1000 CD.
The sample volume defined in the CD determines the sensitivity
Gyrolab Mixing CD 96 integrates and automates sample pretreatment into the assay workflow made possible by Gyrolab platforms. Automating sample pretreatment and immunoassay workflow at nanoliter scale creates a number of advantages including:
In Gyrolab automated method for detection of leached MabSelect SuRe™ ligands, samples are acidified in Gyrolab Mixing CD 96 to dissociate protein A-IgG complexes. The amount of Protein A is then determined by a sandwich immunoassay.
For anti-drug antibody (ADA) analysis in preclinical or clinical serum samples, the mixing function in the Gyrolab Mixing CD 96 can be used to automate sample pre-treatment for acid dissociation of interfering biotherapeutic. Miniaturization simplifies detection of anti-drug antibodies, even in the presence of a high drug concentration. The individual microstructures integrate the acid dissociation process to minimize variation between samples, while edicated Gyrolab ADA software supports assay development and validation for cut point determination, screening and confirmatory analysis.
Contact Gyros Protein Technologies for assistance with your assay development needs.